Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) Return on Equity (2023 - 2025)

Immunome (IMNM) has disclosed Return on Equity for 3 consecutive years, with 0.5% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity rose 105.0% year-over-year to 0.5%, compared with a TTM value of 0.5% through Dec 2025, up 105.0%, and an annual FY2025 reading of 0.55%, up 148.0% over the prior year.
  • Return on Equity was 0.5% for Q4 2025 at Immunome, up from 0.88% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.5% in Q4 2025 and bottomed at 1.74% in Q4 2023.
  • Average Return on Equity over 3 years is 1.1%, with a median of 1.01% recorded in 2024.
  • The sharpest move saw Return on Equity rose 19bps in 2024, then surged 105bps in 2025.
  • Year by year, Return on Equity stood at 1.74% in 2023, then increased by 11bps to 1.54% in 2024, then soared by 68bps to 0.5% in 2025.
  • Business Quant data shows Return on Equity for IMNM at 0.5% in Q4 2025, 0.88% in Q3 2025, and 0.78% in Q2 2025.